Key result
RASi use is linked to ~60% lower mortality in patients with cholangiocarcinoma and hypertension.
Why the study?
Hypertension is a risk factor for cholangiocarcinoma, but the effect of anti-hypertensive drugs on cholangiocarcinoma prognosis remains unclear.
Does RASis usage improve progression-free and overall survival in patients with concurrent cholangiocarcinoma and hypertension undergoing radical surgery?
Cohort (n=102)
No
Does RASis usage improve progression-free and overall survival in patients with concurrent cholangiocarcinoma and hypertension undergoing radical surgery?
Hazard Ratio: 0.4 (95% CI 0.2–0.79)
p-value: p=0.008
Renin-angiotensin system inhibitors are associated with improved progression-free and overall survival in patients with concurrent cholangiocarcinoma and hypertension.
May support RASis consideration in hypertensive cholangiocarcinoma post-surgery; hypothesis-generating and requires prospective confirmation.
BACKGROUND: Hypertension is a risk factor for cholangiocarcinoma (CCA). The effect of anti-hypertensive drugs on the prognosis of CCA is not clear. METHODS: This is a retrospective study of 102 patients (56.9% males, median age 66 years) diagnosed with CCA and hypertension concurrently and received radical surgery (R0), with a median follow-up of 36.7 months. Kaplan-Meier analysis, Cox regressions, and propensity score (PS) matching were applied for statistical analysis. RESULTS: Results of multivariable cox analysis showed that renin-angiotensin system inhibitors (RASis) usage was a protective factor for progression-free survival (PFS) (hazard ratio [HR] = 0.55, 95% confidence interval [95% CI]: 0.32-0.96) and overall survival (OS) (HR = 0.40, 95% CI: 0.20-0.79), respectively. Calcium channel blockers, diuretics, and β-blockers didn't show significant associations. The association of RASis usage and PFS and OS was derived by PS matching, with a cohort of 28 RASis users and 56 RASis non-users. The median PFS and OS of RASis users (PFS, 17.6 months (9.2-34.4); OS, 24.8 months (16.5-42.3)) were longer than RASis non-users (PFS, 10.5 months (4.1-24.1); OS, 14.6 months (10.6-28.4)). The 1 year, 2 years, and 3 years' survival rates of RASis users (89.1%, 77.0%, and 65.5%) were higher than RASis non-users (70.9%, 54.0%, and 40.0%). CONCLUSIONS: RASis usage improves the survival of patients with CCA and hypertension concurrently.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2023) conducted a cohort in Cholangiocarcinoma and hypertension (n=102). Renin-angiotensin system inhibitors vs. RASis non-users was evaluated on Overall survival (OS) (HR 0.40, 95% CI 0.20-0.79, p=0.008). Renin-angiotensin system inhibitors usage was associated with significantly improved overall survival (HR 0.40) in patients with concurrent cholangiocarcinoma and hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: